<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02724956</url>
  </required_header>
  <id_info>
    <org_study_id>2017-0449</org_study_id>
    <secondary_id>HSC-MS-14-0970</secondary_id>
    <nct_id>NCT02724956</nct_id>
  </id_info>
  <brief_title>Ambu AuraGain and Teleflex LMA Protector Fiberoptic Assessments in Elective Patients</brief_title>
  <official_title>Randomized Comparison of Ambu AuraGain and Teleflex Protector Using Clinical and Fiberoptic Assessments in Elective Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ambu A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Participant is being asked to take part in this study because participant is going to have&#xD;
      surgery that requires general anesthesia (in which participant is unconscious for the&#xD;
      procedure).&#xD;
&#xD;
      During surgery, anesthesiologists often place a supraglottic airway device (SGAD). An SGAD is&#xD;
      a device that helps participant breathe and may help the anesthesiologist put a breathing&#xD;
      tube in participant's airway while participant is asleep during surgery. There are many&#xD;
      different kinds of SGADs that are readily available for use by anesthesiologists during&#xD;
      surgery. The SGADs that are being studied are the Ambu Auragain and the Teleflex LMA&#xD;
      Protector.&#xD;
&#xD;
      The goal of this clinical research study is to compare the effectiveness of both devices.&#xD;
&#xD;
      This is an investigational study. Both of the SGADs that are being used on this study are FDA&#xD;
      approved and are frequently used for the surgery that participant is going to have. It is&#xD;
      investigational to compare the 2 devices.&#xD;
&#xD;
      Up to 50 participants will be enrolled in this study. All will take part at MD Anderson.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Surgery:&#xD;
&#xD;
      Participant will sign a separate consent form for surgery that describes the procedure and&#xD;
      its risks. Participant will receive anesthesia through a catheter (sterile flexible tube) in&#xD;
      one of participant's veins. During the procedure, participant's vital signs (heart rate,&#xD;
      blood pressure, oxygen levels) will be monitored.&#xD;
&#xD;
      Study Groups:&#xD;
&#xD;
      If participant agrees to take part in this study, demographic information (such as&#xD;
      participant's age, sex, and race) will be collected.&#xD;
&#xD;
      Participant will be randomly assigned (as in the flip of a coin) to 1 of 2 study groups. This&#xD;
      is done because no one knows if one study group is better, the same, or worse than the other&#xD;
      group. Participant will have an equal (50/50) chance of being assigned to either group. One&#xD;
      group will use the Ambu Auragain, and the other will use the Teleflex LMA Protector.&#xD;
&#xD;
      Study Procedures:&#xD;
&#xD;
      After general anesthesia is given and participant falls asleep, the anesthesiologist will&#xD;
      place the SGAD. The study staff will measure how easy it is to place the SGAD and how long&#xD;
      each different step of the placement takes. Correct placement of the SGAD will be checked&#xD;
      using a device with a small camera to help the doctor see participant's airway on a screen. A&#xD;
      gastric tube will be placed to measure the volume of air and content of the stomach.&#xD;
      Additionally the study doctor may place a breathing tube using the SGAD to make sure air is&#xD;
      moving in and out of participant's lungs.&#xD;
&#xD;
      Participant will then be positioned and prepared for the surgery. The study staff will be&#xD;
      collecting information from the time participant enters the operating room until the time&#xD;
      participant leaves.&#xD;
&#xD;
      Additionally, participant will be interviewed after participant's surgery in the recovery&#xD;
      room once participant is awake. Participant will be asked about any pain or soreness&#xD;
      participant has, as well as any difficulty breathing, swallowing, or talking. This interview&#xD;
      may take up to 5 minutes. Participation in the study will be over after the interview.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 29, 2017</start_date>
  <completion_date type="Actual">December 18, 2020</completion_date>
  <primary_completion_date type="Actual">December 18, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1st Attempt Success With Supraglottic Airway Devices (SGAD)</measure>
    <time_frame>from Anesthesia Start to Anesthesia Stop, approximately 1 hour</time_frame>
    <description>Success defined as correct placement of SGAD. 1st Attempt success of SGAD either Ambu AuraGain or Teleflex LMA Protector during insertion and placement into an airway.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oropharyngeal Leak Pressure (OLP)</measure>
    <time_frame>from Anesthesia Start to Anesthesia Stop, approximately 1 hour</time_frame>
    <description>OLP measured by a portable, handheld manometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Rate of Successful Intubation and Ventilation</measure>
    <time_frame>from Anesthesia Start to Anesthesia Stop, approximately 1 hour</time_frame>
    <description>Rate of successful intubation and ventilation by utilizing the SGAD as an intubation conduit guided by the Ambu® aScope™ 3 Slim.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ease of SGAD Insertion</measure>
    <time_frame>from Anesthesia Start to Anesthesia Stop, approximately 1 hour</time_frame>
    <description>Qualitative Assessment scale range of 1-4. (1) Easy; (2) Resistance, (3) Difficult; and (4) Unsuccessful.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glottic Opening (POGO)</measure>
    <time_frame>from Anesthesia Start to Anesthesia Stop, approximately 1 hour</time_frame>
    <description>POGO Score of 100% on First Attempt at Device Placement. All participant assessments and observations (clinical data) completed and recorded during the 1st visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functionality of Gastric Tube Placement</measure>
    <time_frame>from Anesthesia Start to Anesthesia Stop, approximately 1 hour</time_frame>
    <description>Functionality of gastric drainage channel which will be inserted through the appropriate channel of the SGAD.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Ambu AuraGain</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SGAD placement using Ambu AuraGain&#xD;
Lubricate airway tube of SGAD &amp; pass the aScope through until visualization of the carina.&#xD;
Standard Parker Flex Tip endotracheal tube (ETT) size 6.0, 7.0, and 8.0 mm ETT will be used as per anesthesiologist preference.&#xD;
Pass ETT tube down the insertion cord of the Ambu aScope &amp; verify placement.&#xD;
Inflate cuff and remove aScope.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Teleflex LMA Protector</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SGAD placement using the Teleflex LMA Protector&#xD;
Lubricate airway tube of SGAD &amp; pass the aScope through until visualization of the carina.&#xD;
Standard Parker Flex Tip ETT size 6.0 and 7.0 mm. ETT will be used as per anesthesiologist preference.&#xD;
Pass ETT tube down the insertion cord of the Ambu aScope &amp; verify placement.&#xD;
Inflate cuff and remove aScope.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ambu AuraGain</intervention_name>
    <description>Pre-curved, rigid airway tube, SGAD. Third generation Ambu laryngeal mask satisfying 3 fundamental airway management needs by integrating gastric access and intubation capability in an anatomically curved single-use device that facilitates rapid establishment of a safe airway. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.</description>
    <arm_group_label>Ambu AuraGain</arm_group_label>
    <other_name>Supraglottic airway device</other_name>
    <other_name>SGAD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Teleflex LMA Protector</intervention_name>
    <description>Pre-curved, rigid airway tube, SGAD: A next-generation, single-use laryngeal mask with a dual gastric drainage channel and pharyngeal chamber. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.</description>
    <arm_group_label>Teleflex LMA Protector</arm_group_label>
    <other_name>LMA® Protector™</other_name>
    <other_name>Supraglottic airway device</other_name>
    <other_name>SGAD</other_name>
    <other_name>LMA</other_name>
    <other_name>laryngeal mask airway</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ambu aScope</intervention_name>
    <description>Flexible scope which will be introduced into airway tube and guided through the SGAD until it will be possible to view the vocal cords. Description of the maximal optical view will be measured by the Percentage of Glottic Opening (POGO).</description>
    <arm_group_label>Ambu AuraGain</arm_group_label>
    <arm_group_label>Teleflex LMA Protector</arm_group_label>
    <other_name>Ambu® aScope™ 3 Slim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 years of age or older&#xD;
&#xD;
          2. Scheduled for an elective surgery requiring general anesthesia&#xD;
&#xD;
          3. Scheduled surgery &lt; 4hrs&#xD;
&#xD;
          4. American Society of Anesthesiology (ASA) Physical Status I-III&#xD;
&#xD;
          5. Body Mass Index (BMI) &lt; 30 kg/m2&#xD;
&#xD;
          6. Mallampati I-III&#xD;
&#xD;
          7. Able to bite upper lip via Upper Lip Bite Test (ULBT)&#xD;
&#xD;
          8. Inter-incisor distance &gt; 2.5cm&#xD;
&#xD;
          9. Thyromental distance &gt; 6cm&#xD;
&#xD;
         10. Full range of motion in the neck&#xD;
&#xD;
         11. Has provided written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Under the age of 18 years old&#xD;
&#xD;
          2. ASA IV-V&#xD;
&#xD;
          3. Require prone positioning for surgery&#xD;
&#xD;
          4. Scheduled surgery &gt; 4hrs&#xD;
&#xD;
          5. Liquid only diet &lt; 2hrs and/or solids &lt; 8hrs&#xD;
&#xD;
          6. High risk of regurgitation&#xD;
&#xD;
          7. Exhibits signs of respiratory tract pathology (including a sore throat preoperatively)&#xD;
&#xD;
          8. Mallampati IV&#xD;
&#xD;
          9. Unable to bite upper lip via Upper Lip Bite Test (ULBT)&#xD;
&#xD;
         10. Inter-incisor distance &lt; 2.5cm&#xD;
&#xD;
         11. Thyromental distance &lt; 6cm&#xD;
&#xD;
         12. Limited neck movement&#xD;
&#xD;
         13. Airway pathology/facial abnormality&#xD;
&#xD;
         14. Has been diagnosed with/exhibits any mental neurological disorder/disease/condition&#xD;
             that would prevent participation in the study in the opinion of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carin A Hagberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>The University of Texas (UT) MD Anderson Cancer Center Official Website</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 22, 2016</study_first_submitted>
  <study_first_submitted_qc>March 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2016</study_first_posted>
  <results_first_submitted>July 7, 2021</results_first_submitted>
  <results_first_submitted_qc>August 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 31, 2021</results_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>supraglottic airway device (SGAD) insertion</keyword>
  <keyword>SGAD</keyword>
  <keyword>ventilation and intubation</keyword>
  <keyword>gastric drainage channel</keyword>
  <keyword>fiberoptic assessment</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT02724956/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ambu AuraGain</title>
          <description>Pre-curved, rigid airway tube, SGAD. Third generation Ambu laryngeal mask satisfying 3 fundamental airway management needs by integrating gastric access and intubation capability in an anatomically curved single-use device that facilitates rapid establishment of a safe airway. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.</description>
        </group>
        <group group_id="P2">
          <title>Teleflex LMA Protector</title>
          <description>Pre-curved, rigid airway tube, SGAD: A next-generation, single-use laryngeal mask with a dual gastric drainage channel and pharyngeal chamber. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ambu AuraGain</title>
          <description>SGAD placement using Ambu AuraGain&#xD;
Lubricate airway tube of SGAD &amp; pass the aScope through until visualization of the carina.&#xD;
Standard Parker Flex Tip endotracheal tube (ETT) size 6.0, 7.0, and 8.0 mm ETT will be used as per anesthesiologist preference.&#xD;
Pass ETT tube down the insertion cord of the Ambu aScope &amp; verify placement.&#xD;
Inflate cuff and remove aScope.&#xD;
Ambu AuraGain: Pre-curved, rigid airway tube, SGAD. Third generation Ambu laryngeal mask satisfying 3 fundamental airway management needs by integrating gastric access and intubation capability in an anatomically curved single-use device that facilitates rapid establishment of a safe airway. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.&#xD;
Ambu aScope: Flexible scope which will be introduced into airway tube and guided through the SGAD until it will be possible to view the vocal cords. Description of the maximal optical view will be measured by the Percentage of Glottic Opening (POGO).</description>
        </group>
        <group group_id="B2">
          <title>Teleflex LMA Protector</title>
          <description>SGAD placement using the Teleflex LMA Protector&#xD;
Lubricate airway tube of SGAD &amp; pass the aScope through until visualization of the carina.&#xD;
Standard Parker Flex Tip ETT size 6.0 and 7.0 mm. ETT will be used as per anesthesiologist preference.&#xD;
Pass ETT tube down the insertion cord of the Ambu aScope &amp; verify placement.&#xD;
Inflate cuff and remove aScope.&#xD;
Teleflex LMA Protector: Pre-curved, rigid airway tube, SGAD: A next-generation, single-use laryngeal mask with a dual gastric drainage channel and pharyngeal chamber. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.&#xD;
Ambu aScope: Flexible scope which will be introduced into airway tube and guided through the SGAD until it will be possible to view the vocal cords. Description of the maximal optical view will be measured by the Percentage of Glottic Opening (POGO).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="24"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="24"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="24"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Supraglottic Airway (SGA) Sizes</title>
          <description>Size 3: 30-50 kg, Size 4: 50-70 kg, and Size 5: 70-100 kg</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>SGA Size 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="24"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SGA Size 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="24"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SGA Size 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="24"/>
                    <count group_id="B3" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>1st Attempt Success With Supraglottic Airway Devices (SGAD)</title>
        <description>Success defined as correct placement of SGAD. 1st Attempt success of SGAD either Ambu AuraGain or Teleflex LMA Protector during insertion and placement into an airway.</description>
        <time_frame>from Anesthesia Start to Anesthesia Stop, approximately 1 hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ambu AuraGain</title>
            <description>Pre-curved, rigid airway tube, SGAD. Third generation Ambu laryngeal mask satisfying 3 fundamental airway management needs by integrating gastric access and intubation capability in an anatomically curved single-use device that facilitates rapid establishment of a safe airway. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.</description>
          </group>
          <group group_id="O2">
            <title>Teleflex LMA Protector</title>
            <description>Pre-curved, rigid airway tube, SGAD: A next-generation, single-use laryngeal mask with a dual gastric drainage channel and pharyngeal chamber. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.</description>
          </group>
        </group_list>
        <measure>
          <title>1st Attempt Success With Supraglottic Airway Devices (SGAD)</title>
          <description>Success defined as correct placement of SGAD. 1st Attempt success of SGAD either Ambu AuraGain or Teleflex LMA Protector during insertion and placement into an airway.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Successful</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unsuccessful</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oropharyngeal Leak Pressure (OLP)</title>
        <description>OLP measured by a portable, handheld manometer.</description>
        <time_frame>from Anesthesia Start to Anesthesia Stop, approximately 1 hour</time_frame>
        <population>8 participants were not recorded due to protocol deviation</population>
        <group_list>
          <group group_id="O1">
            <title>Ambu AuraGain</title>
            <description>Pre-curved, rigid airway tube, SGAD. Third generation Ambu laryngeal mask satisfying 3 fundamental airway management needs by integrating gastric access and intubation capability in an anatomically curved single-use device that facilitates rapid establishment of a safe airway. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.</description>
          </group>
          <group group_id="O2">
            <title>Teleflex LMA Protector</title>
            <description>Pre-curved, rigid airway tube, SGAD: A next-generation, single-use laryngeal mask with a dual gastric drainage channel and pharyngeal chamber. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.</description>
          </group>
        </group_list>
        <measure>
          <title>Oropharyngeal Leak Pressure (OLP)</title>
          <description>OLP measured by a portable, handheld manometer.</description>
          <population>8 participants were not recorded due to protocol deviation</population>
          <units>cmH2O</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="22.00" upper_limit="68.00"/>
                    <measurement group_id="O2" value="37" lower_limit="15.00" upper_limit="56.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Rate of Successful Intubation and Ventilation</title>
        <description>Rate of successful intubation and ventilation by utilizing the SGAD as an intubation conduit guided by the Ambu® aScope™ 3 Slim.</description>
        <time_frame>from Anesthesia Start to Anesthesia Stop, approximately 1 hour</time_frame>
        <population>1 participant was not analyzed in the Teleflex LMA Protector Arm due to device failure</population>
        <group_list>
          <group group_id="O1">
            <title>Ambu AuraGain</title>
            <description>Pre-curved, rigid airway tube, SGAD. Third generation Ambu laryngeal mask satisfying 3 fundamental airway management needs by integrating gastric access and intubation capability in an anatomically curved single-use device that facilitates rapid establishment of a safe airway. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.</description>
          </group>
          <group group_id="O2">
            <title>Teleflex LMA Protector</title>
            <description>Pre-curved, rigid airway tube, SGAD: A next-generation, single-use laryngeal mask with a dual gastric drainage channel and pharyngeal chamber. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Rate of Successful Intubation and Ventilation</title>
          <description>Rate of successful intubation and ventilation by utilizing the SGAD as an intubation conduit guided by the Ambu® aScope™ 3 Slim.</description>
          <population>1 participant was not analyzed in the Teleflex LMA Protector Arm due to device failure</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Successful</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unsuccessful</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ease of SGAD Insertion</title>
        <description>Qualitative Assessment scale range of 1-4. (1) Easy; (2) Resistance, (3) Difficult; and (4) Unsuccessful.</description>
        <time_frame>from Anesthesia Start to Anesthesia Stop, approximately 1 hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ambu AuraGain</title>
            <description>Pre-curved, rigid airway tube, SGAD. Third generation Ambu laryngeal mask satisfying 3 fundamental airway management needs by integrating gastric access and intubation capability in an anatomically curved single-use device that facilitates rapid establishment of a safe airway. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.</description>
          </group>
          <group group_id="O2">
            <title>Teleflex LMA Protector</title>
            <description>Pre-curved, rigid airway tube, SGAD: A next-generation, single-use laryngeal mask with a dual gastric drainage channel and pharyngeal chamber. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ease of SGAD Insertion</title>
          <description>Qualitative Assessment scale range of 1-4. (1) Easy; (2) Resistance, (3) Difficult; and (4) Unsuccessful.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Easy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difficult</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unsuccessful</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glottic Opening (POGO)</title>
        <description>POGO Score of 100% on First Attempt at Device Placement. All participant assessments and observations (clinical data) completed and recorded during the 1st visit</description>
        <time_frame>from Anesthesia Start to Anesthesia Stop, approximately 1 hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ambu AuraGain</title>
            <description>Pre-curved, rigid airway tube, SGAD. Third generation Ambu laryngeal mask satisfying 3 fundamental airway management needs by integrating gastric access and intubation capability in an anatomically curved single-use device that facilitates rapid establishment of a safe airway. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.</description>
          </group>
          <group group_id="O2">
            <title>Teleflex LMA Protector</title>
            <description>Pre-curved, rigid airway tube, SGAD: A next-generation, single-use laryngeal mask with a dual gastric drainage channel and pharyngeal chamber. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.</description>
          </group>
        </group_list>
        <measure>
          <title>Glottic Opening (POGO)</title>
          <description>POGO Score of 100% on First Attempt at Device Placement. All participant assessments and observations (clinical data) completed and recorded during the 1st visit</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>POGO- Observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POGO- Not Observed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functionality of Gastric Tube Placement</title>
        <description>Functionality of gastric drainage channel which will be inserted through the appropriate channel of the SGAD.</description>
        <time_frame>from Anesthesia Start to Anesthesia Stop, approximately 1 hour</time_frame>
        <population>1 participant was not analyzed in the Teleflex LMA Protector Arm due to device failure</population>
        <group_list>
          <group group_id="O1">
            <title>Ambu AuraGain</title>
            <description>Pre-curved, rigid airway tube, SGAD. Third generation Ambu laryngeal mask satisfying 3 fundamental airway management needs by integrating gastric access and intubation capability in an anatomically curved single-use device that facilitates rapid establishment of a safe airway. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.</description>
          </group>
          <group group_id="O2">
            <title>Teleflex LMA Protector</title>
            <description>Pre-curved, rigid airway tube, SGAD: A next-generation, single-use laryngeal mask with a dual gastric drainage channel and pharyngeal chamber. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.</description>
          </group>
        </group_list>
        <measure>
          <title>Functionality of Gastric Tube Placement</title>
          <description>Functionality of gastric drainage channel which will be inserted through the appropriate channel of the SGAD.</description>
          <population>1 participant was not analyzed in the Teleflex LMA Protector Arm due to device failure</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Easy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Resistance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difficult</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unsuccessful</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>during the 1st visit, up to 60 minutes</time_frame>
      <desc>no reportable AE's/SAE's for this study</desc>
      <group_list>
        <group group_id="E1">
          <title>Ambu AuraGain</title>
          <description>Pre-curved, rigid airway tube, SGAD. Third generation Ambu laryngeal mask satisfying 3 fundamental airway management needs by integrating gastric access and intubation capability in an anatomically curved single-use device that facilitates rapid establishment of a safe airway. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.</description>
        </group>
        <group group_id="E2">
          <title>Teleflex LMA Protector</title>
          <description>Pre-curved, rigid airway tube, SGAD: A next-generation, single-use laryngeal mask with a dual gastric drainage channel and pharyngeal chamber. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Carin Hagberg, MD/Chief Academic Officer, CAO Office</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>713-792-5888</phone>
      <email>chagberg@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

